Axitinib Licensed by Pfizer

Catalog No.S1005

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Price Stock Quantity  
USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Axitinib Chemical Structure

Axitinib Chemical Structure
Molecular Weight: 386.47

Validation & Quality Control

4 customer reviews :

Quality Control & MSDS

Related Compound Libraries

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Axitinib Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Targets VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)

 View  More

IC50 0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM
In vitro Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cellMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\2e|FKSzVyPUCuNFAxODVzMzFOwG0>Ml\3V2FPT0WU
NCI-H1703NF3sNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTBwMECwPVAzKM7:TR?=MUTTRW5ITVJ?
KASUMI-1M37tXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NInGXG1KSzVyPUCuNFA3QDJizszNM1nNdXNCVkeHUh?=
CGTH-W-1M{TT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUH6V4wxUUN3ME2wMlAxPzJ{IN88US=>NUTNNmhYW0GQR1XS
A204NYjEb241T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PBZmlEPTB;MD6wNFk6OiEQvF2=MmLIV2FPT0WU
HOP-62MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPmVHRKSzVyPUCuNVA5OzZizszNM2DpNXNCVkeHUh?=
H-EMC-SSNV73TJJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFTkdJRKSzVyPUCuNVExODVizszNMorMV2FPT0WU
KU812NFrYfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\NTWM2OD1yLkG2OVc4KM7:TR?=MVvTRW5ITVJ?
EM-2NFuwRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1:2UWlEPTB;MD6xOlgyPiEQvF2=M3XzeXNCVkeHUh?=
LAMA-84M2PYTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vSTWlEPTB;MD6xO|Y3PSEQvF2=NUTpTpZ5W0GQR1XS
JARNHHwemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwMkO5PFkh|ryPNXTyZnVZW0GQR1XS
G-361NHfD[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHpbZpKSzVyPUCuN|I{OjVizszNMnPhV2FPT0WU
KG-1M1\6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTBwM{e2OFIh|ryPM4naWXNCVkeHUh?=
BV-173Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnaUlEzUUN3ME2wMlM6OzJizszNNIG1fYxUSU6JRWK=
K5NGG3UIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTBwNEKxNlch|ryPMWrTRW5ITVJ?
MEG-01MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGi2UFBKSzVyPUCuOFI{PjFizszNM4PQSXNCVkeHUh?=
MFM-223NUXqV2IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LDdmlEPTB;MD60OFc4PiEQvF2=MorzV2FPT0WU
BE-13NVu1fmNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwNUGwNFgh|ryPMVfTRW5ITVJ?
NEC8NXHmdG02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTBwN{KxNVMh|ryPM4jQVnNCVkeHUh?=
SW756NX63N4xTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmrpTWM2OD1yLkm5PFQ3KM7:TR?=NI\3c5JUSU6JRWK=
A2780M3PINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHaTWM2OD1zLkCxNVQ3KM7:TR?=MkniV2FPT0WU
NB14NX:1cY5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF6wRodKSzVyPUGuNFE5ODFizszNMnn2V2FPT0WU
H4MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MULJR|UxRTFwME[0NlIh|ryPMnnGV2FPT0WU
SK-OV-3NWq0foJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvicoNoUUN3ME2xMlA3PjN|IN88US=>Mkf5V2FPT0WU
AN3-CANIrORZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXixeW9iUUN3ME2xMlA5Ozh7IN88US=>NW\NRVNiW0GQR1XS
A427NWmxfXFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDBTWM2OD1zLkGwN|gyKM7:TR?=NFTmUnZUSU6JRWK=
ES7NEXaOIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPqcnVOUUN3ME2xMlEyOzN2IN88US=>MmPhV2FPT0WU
AGSNY\3SZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4O1PGlEPTB;MT6xNVM6PSEQvF2=MU\TRW5ITVJ?
G-402NHnyWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGDNOZFKSzVyPUGuNVQ3QTRizszNM{LZWHNCVkeHUh?=
ES5NX7HS2pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXrd|FKSzVyPUGuNVczPDhizszNNFi4cphUSU6JRWK=
DELMWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHQTWM2OD1zLkK1OFU4KM7:TR?=NXzTVo9IW0GQR1XS
NB10NHT2NmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHP4PGtKSzVyPUGuN|I2PTdizszNNGT1RXNUSU6JRWK=
NCI-H1581NF7jXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPqXI5FUUN3ME2xMlM6ODR{IN88US=>MkTiV2FPT0WU
D-566MGMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml71TWM2OD1zLkSwOlg{KM7:TR?=NXLRXJA6W0GQR1XS
LXF-289MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{LnVWlEPTB;MT60N|k6PiEQvF2=M2G4PXNCVkeHUh?=
BT-549NXHJVnpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTFwNU[5NFkh|ryPMnjlV2FPT0WU
NKM-1MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfwTGNKSzVyPUGuOlA2PTZizszNMYXTRW5ITVJ?
SW780NXnaRZlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHnmUmRKSzVyPUGuOlUyPThizszNNH\kcnBUSU6JRWK=
NCI-H292MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTFwNk[zPFMh|ryPM1\aSnNCVkeHUh?=
HMV-IIM1jXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnpTWM2OD1zLkewOFg5KM7:TR?=MYHTRW5ITVJ?
ALL-POMXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkC5TWM2OD1zLkiwNFE2KM7:TR?=NXX2b4F3W0GQR1XS
UACC-257NFflPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfLUopNUUN3ME2xMlgzOTZ|IN88US=>NH\qNIxUSU6JRWK=
PA-1NVnsS49DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzWUVlKSzVyPUGuPFI4OjVizszNM3G1NXNCVkeHUh?=
HD-MY-ZMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTFwOE[yPFEh|ryPMkH6V2FPT0WU
HSC-4M4HMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2LYdmlEPTB;MT65N|g{QSEQvF2=MlixV2FPT0WU
GCTMlT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH62eoxKSzVyPUKuNFA6OTZizszNMnLTV2FPT0WU
RT-112NYGyTZR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfkS2lvUUN3ME2yMlE{PDJ2IN88US=>Mn\oV2FPT0WU
A172NU\LO|B1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\VV2lEPTB;Mj6xN|YxPiEQvF2=MXTTRW5ITVJ?
HCE-TMUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlG1TWM2OD1{LkKwOVk5KM7:TR?=MXnTRW5ITVJ?
YH-13MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYrPPYJCUUN3ME2yMlIyPjdzIN88US=>MlPHV2FPT0WU
DK-MGMoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;K[3c1UUN3ME2yMlI{QDN2IN88US=>MWfTRW5ITVJ?
ACNMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnUTWM2OD1{LkKzPFc2KM7:TR?=M1viUXNCVkeHUh?=
VA-ES-BJMl;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIXQPG1KSzVyPUKuNlQ6PTdizszNM2PFXXNCVkeHUh?=
L-363NGHXbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3yySWlEPTB;Mj6yPFA3OSEQvF2=NHzSdIVUSU6JRWK=
HuH-7NV62RlF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1K0PWlEPTB;Mj60NlE3PSEQvF2=M{jKUnNCVkeHUh?=
A4-FukMkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmGyTWM2OD1{LkS3NVY5KM7:TR?=NH;3RZdUSU6JRWK=
T-24NUmyPGRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEDGPFBKSzVyPUKuOFgxOzdizszNM37PO3NCVkeHUh?=
GOTONYnJfYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVjMTHN[UUN3ME2yMlU{ODF|IN88US=>NIXDcVFUSU6JRWK=
MV-4-11MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTJwNUmxOlkh|ryPNInIc|JUSU6JRWK=
DMS-114MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFLkXWNKSzVyPUKuOlY{PDVizszNM3HjcnNCVkeHUh?=
MHH-NB-11NGnGSnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\6dGlEPTB;Mj63NFI6QSEQvF2=MoPxV2FPT0WU
CHP-212MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rrUGlEPTB;Mj64NlA6OSEQvF2=NVLlUVdqW0GQR1XS
DMS-273NEPrfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jwO2lEPTB;Mj65NFIxPyEQvF2=NGXuRZRUSU6JRWK=
SF295NFTZbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTU[4NpUUN3ME2zMlAzPTl5IN88US=>NGnEWYVUSU6JRWK=
NCI-H1563NHzIfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGGycnpKSzVyPUOuNVUxODVizszNMVrTRW5ITVJ?
NCI-H446MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInrVWpKSzVyPUOuNlI5ODVizszNMnqyV2FPT0WU
HCC1806M3nY[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTNwMke2OVch|ryPMVPTRW5ITVJ?
SF126NUX5TGpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{[5ZWlEPTB;Mz6zNFAyPyEQvF2=NVftN|FGW0GQR1XS
SW982M4j0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;XTWM2OD1|LkOzPFc2KM7:TR?=M4DwWHNCVkeHUh?=
ES8MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTNwM{S5PVkh|ryPNF;wVnlUSU6JRWK=
SCC-4Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TSd2lEPTB;Mz61NFM6PiEQvF2=MnXqV2FPT0WU
RPMI-8226NEfsSJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3XTWM2OD1|Lk[yOlE3KM7:TR?=NInpc5hUSU6JRWK=
EW-11MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HQXWlEPTB;Mz62N|AzOiEQvF2=MXjTRW5ITVJ?
COR-L105M{nGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PPO2lEPTB;Mz62N|M{PCEQvF2=Ml3SV2FPT0WU
ES1NU[welBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTHeJlvUUN3ME2zMlg{ODl2IN88US=>NInmVIpUSU6JRWK=
KMOE-2NEjNR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTNwOUG4NFgh|ryPMl63V2FPT0WU
ABC-1MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnKyTWM2OD1|LkmzPVEyKM7:TR?=M1jCc3NCVkeHUh?=
NCI-H526MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPXXGxKSzVyPUOuPVkyOjZizszNMn3HV2FPT0WU
HCC1395Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrZbYVKSzVyPUOuPVk1QDRizszNMVfTRW5ITVJ?
DU-145NF;hXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWr6WHpiUUN3ME20MlEzQDJ3IN88US=>M1TOVnNCVkeHUh?=
JEG-3M1\nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTRwMUW5NVYh|ryPMlzmV2FPT0WU
HCC1187NYTtR3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTRwMkG1PVch|ryPMnTsV2FPT0WU
LC-2-adNGXmPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTRwMkKxO|ch|ryPMnHRV2FPT0WU
ONS-76NGe3PJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTRwMkSxPVIh|ryPMlThV2FPT0WU
CAL-27NVnVPWNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\3fWlEPTB;ND6yOFM1PCEQvF2=NF[xU|ZUSU6JRWK=
8-MG-BAMmfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XrRmlEPTB;ND6yOlY2QCEQvF2=MVXTRW5ITVJ?
HGC-27MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWj5SoVQUUN3ME20MlI6PjZizszNMVTTRW5ITVJ?
Hs-578-TNW\Z[oxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPsTWM2OD12LkOxOFY5KM7:TR?=NIKwR21USU6JRWK=
EW-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXvTWM2OD12LkWzNFE1KM7:TR?=NIC3NXZUSU6JRWK=
SW1573MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoDMTWM2OD12LkW1NVY{KM7:TR?=MljYV2FPT0WU
SNU-423NYGyeJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTRwNkC3PUDPxE1?NGDCbGxUSU6JRWK=
HOSM4D4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\2VldKSzVyPUSuOlk4PyEQvF2=NY\U[5l[W0GQR1XS
LB1047-RCCNY\aU|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETkPJJKSzVyPUSuPFE1OThizszNMmfRV2FPT0WU
ChaGo-K-1NGnWblhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLPTWM2OD12Lki5NFQ5KM7:TR?=NXu5NIRoW0GQR1XS
A3-KAWNGXRVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYfJR|UxRTRwOUezOVIh|ryPNHfIZZpUSU6JRWK=
CAS-1NUHX[2Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFn1VZZKSzVyPUSuPVk6ODhizszNNEO5bWVUSU6JRWK=
NBsusSRMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnfVTWM2OD13LkCzOVE1KM7:TR?=NFjwUmtUSU6JRWK=
KM12MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzTTWM2OD13LkK5PFI4KM7:TR?=NG\NemlUSU6JRWK=
NCI-H1155M1jRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrETWM2OD13LkO4NVg2KM7:TR?=NIXHTW9USU6JRWK=
EFM-19M1Tofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTVwNEG3N|ch|ryPNYTxbnczW0GQR1XS
D-392MGM1rxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvJTXFTUUN3ME21MlU4QDR7IN88US=>MmPJV2FPT0WU
JVM-3NX3UVHh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWO0cG1tUUN3ME21MlczOzJ3IN88US=>M1HFWXNCVkeHUh?=
EW-16NIHwOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\teGlEPTB;NT63OVU5OyEQvF2=MkDPV2FPT0WU
KARPAS-45NIraVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYX6fYNbUUN3ME21Mlg1OzJ3IN88US=>NH\XUJBUSU6JRWK=
NCI-H28MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVe4VmJMUUN3ME21Mlg4QTF6IN88US=>NWrMWGRwW0GQR1XS
COLO-829Mm\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTVwOUG1NFQh|ryPNFzibJVUSU6JRWK=
KM-H2MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\4d4VKSzVyPUWuPVI{QTVizszNMUnTRW5ITVJ?
NCI-H82Ml;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\ZTWM2OD13LkmyO|cyKM7:TR?=NIfuVIFUSU6JRWK=
OAW-42MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLsfGVJUUN3ME21Mlk5QDJzIN88US=>NYTYTok4W0GQR1XS
A704MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFW5eIZKSzVyPU[uNVA2PzRizszNMXvTRW5ITVJ?
NCI-H1048NU\lblZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH:xVGlKSzVyPU[uNVA2QTlizszNMXzTRW5ITVJ?
LOXIMVINH3BTZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXuwd3VrUUN3ME22MlEyOjR6IN88US=>M{O4dHNCVkeHUh?=
MKN45MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXGxcIxyUUN3ME22MlI3ODF4IN88US=>NVzwNnF4W0GQR1XS
D-502MGMnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLyUVJOUUN3ME22MlI5QDV5IN88US=>NWnWPJlRW0GQR1XS
HUTU-80Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzhT25RUUN3ME22MlQyPjh6IN88US=>M37VRXNCVkeHUh?=
S-117NHTJTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU[1XIFIUUN3ME22MlUxOjZ5IN88US=>MnrLV2FPT0WU
HCC1569MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTZwNUO3N|ch|ryPMlz5V2FPT0WU
J-RT3-T3-5M2rOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTZwNUS1O|Ih|ryPMl35V2FPT0WU
OC-314NY\EUJZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHWTW83UUN3ME22MlkyOTV7IN88US=>M17W[nNCVkeHUh?=
SNU-449M3K4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjRdndpUUN3ME23MlAyODd{IN88US=>M{LZWHNCVkeHUh?=
NCI-H720MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnxXHhIUUN3ME23MlE6OzR3IN88US=>MlfCV2FPT0WU
KP-N-YSMonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zFO2lEPTB;Nz6yNFczKM7:TR?=NIOweVhUSU6JRWK=
IGROV-1NF7pfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTdwM{KzPFYh|ryPNInVUWRUSU6JRWK=
SK-PN-DWMnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HQSGlEPTB;Nz60PFE2KM7:TR?=Mk[zV2FPT0WU
HCC1419MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULtZW1ZUUN3ME23MlU{KM7:TR?=NF3LfVlUSU6JRWK=
HAL-01Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLlSYJ3UUN3ME23MlYxPjR2IN88US=>MVXTRW5ITVJ?
HCC2998M3Hu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuxPZdKSzVyPUeuOlA4PDNizszNNV7WVFN4W0GQR1XS
SK-N-FINXW1[2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;oe2lDUUN3ME23MlY{ODN|IN88US=>MlHmV2FPT0WU
GI-ME-NMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTdwNkS5N|Qh|ryPM3rSeXNCVkeHUh?=
SW1088NVvlXFJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkntTWM2OD15Lk[1PFI3KM7:TR?=NYHpWpp4W0GQR1XS
IA-LMMVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV36b4Z2UUN3ME23MlY5PjF|IN88US=>MWDTRW5ITVJ?
SK-NEP-1NVrKd2pWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mle0TWM2OD15Lk[5OlEh|ryPMmmyV2FPT0WU
MDA-MB-415MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTdwOEmxPFYh|ryPMkLyV2FPT0WU
COLO-800MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTdwOUS0PVIh|ryPM3HzfXNCVkeHUh?=
NCI-H2228NI\OZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVPJR|UxRThwMUW3PFMh|ryPNUX1b2pYW0GQR1XS
D-423MGMl\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPk[IxKSzVyPUiuNlE4OiEQvF2=M4TmNnNCVkeHUh?=
TE-1M4HTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYe2e4dRUUN3ME24MlQ1OzF4IN88US=>M3vFTXNCVkeHUh?=
NOS-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRThwNUG1N|Qh|ryPM2HSWXNCVkeHUh?=
8505CM{\5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfQUIlKSzVyPUiuOlQ5OjRizszNMnfsV2FPT0WU
HEC-1MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRThwN{i0N|kh|ryPMXXTRW5ITVJ?
TE-11NVP2bFJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPnTWM2OD16Lkm5OVUyKM7:TR?=MkHOV2FPT0WU
CTB-1NUHGUFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTlwMEG0N|Mh|ryPMXLTRW5ITVJ?
TGBC11TKBNIPE[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTlwMEKyOFEh|ryPM1fYZXNCVkeHUh?=
NB17NHTzNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGn6UWZKSzVyPUmuNVg5PyEQvF2=NUe5d4tUW0GQR1XS
BeckerMmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;ibmlEPTB;OT60NVk1PCEQvF2=MVzTRW5ITVJ?
SN12CMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7NRo9KSzVyPUmuOFUzOzRizszNNHK5UYdUSU6JRWK=
COLO-320-HSRMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrBeVNYUUN3ME25MlYxOjN5IN88US=>MoH1V2FPT0WU
D-283MEDNVfxSWRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4XCcGlEPTB;OT62N|A4OiEQvF2=NX7mR5FEW0GQR1XS
D-263MGM3HvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTlwOEOzPFQh|ryPNGfye|VUSU6JRWK=
MEL-JUSOMmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFm2eJJKSzVyPUmuPVAyOjdizszNMl7aV2FPT0WU
T98GNY[3fGxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTlwOUCyNFMh|ryPMXzTRW5ITVJ?
HLEMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTlwOUC5NFkh|ryPNYLiR2poW0GQR1XS
Ca9-22NWPGe2V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M13RcWlEPTB;MUCuNFY3PSEQvF2=M4LGTnNCVkeHUh?=
OS-RC-2M1;5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3sSmJKSzVyPUGwMlExPDVizszNMV\TRW5ITVJ?
T47DNHXMTWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLOdnNHUUN3ME2xNE4yPTVizszNM3;VbHNCVkeHUh?=
GI-1M{PWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjYeY9xUUN3ME2xNE4{PTN|IN88US=>NGHPOG1USU6JRWK=
NUGC-3MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3myZWlEPTB;MUCuOFQxOiEQvF2=Mlz5V2FPT0WU
MDA-MB-361M3vlOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorQTWM2OD1zMD60OFMzKM7:TR?=NHXJSIVUSU6JRWK=
SCC-15MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1XtR2lEPTB;MUCuOFcyQCEQvF2=NUjHd3Q5W0GQR1XS
KS-1NIrF[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXjVZVUUUN3ME2xNE43OzBzIN88US=>MmjnV2FPT0WU
CAL-12TNFvCXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHwVGtsUUN3ME2xNE43OzZzIN88US=>NXK0PFJUW0GQR1XS
OVCAR-4MkTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4nKUGlEPTB;MUCuO|A3QCEQvF2=NXfnNY84W0GQR1XS
HuP-T4MoTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTFzLkCzNlgh|ryPNFS0V3NUSU6JRWK=
NCI-H358MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTFzLkK2OVch|ryPMnuzV2FPT0WU
HO-1-N-1M2r5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfQZ3pJUUN3ME2xNU4{Ozl6IN88US=>MWDTRW5ITVJ?
NH-12NU[5Woh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2XlZWlEPTB;MUGuOVM4QCEQvF2=M4T4RXNCVkeHUh?=
MOLT-4NEPmcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XMO2lEPTB;MUGuOVk5PSEQvF2=M{Ho[XNCVkeHUh?=
K-562MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1v0XGlEPTB;MUGuO|I1QCEQvF2=M3rkPXNCVkeHUh?=
ES6NVLuSppmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1X5RWlEPTB;MUGuPFU5OSEQvF2=MofiV2FPT0WU
RO82-W-1NVzQcZp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfVZnN4UUN3ME2xNU46ODZ2IN88US=>Mlz0V2FPT0WU
Ramos-2G6-4C10MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYW5W5p[UUN3ME2xNU46OzJizszNM{jW[nNCVkeHUh?=
23132-87NInzZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jm[GlEPTB;MUKuNFgzOSEQvF2=M2OyS3NCVkeHUh?=
A549MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH;yNo5KSzVyPUGyMlMzQDVizszNM2HEN3NCVkeHUh?=
NCI-H23MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDO[JlxUUN3ME2xNk42ODJ4IN88US=>M{HKRXNCVkeHUh?=
H9MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHDPWk{UUN3ME2xNk42PTd5IN88US=>M3qxVXNCVkeHUh?=
LB771-HNCNFPyXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTkTWM2OD1zMj63OlUh|ryPNFXFWJRUSU6JRWK=
QIMR-WILMl;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXQZlVKSzVyPUGyMlgzPThizszNMVvTRW5ITVJ?
HSC-3M3uyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETjVIZKSzVyPUGyMlkzPzZizszNM165bXNCVkeHUh?=
PFSK-1NFvSdGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MU\JR|UxRTF{Lkm1NFch|ryPNIPxN29USU6JRWK=
ETK-1MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jqdGlEPTB;MUOuNFc4QSEQvF2=NEGxT3hUSU6JRWK=
SW1710NHzzc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXTR[pRFUUN3ME2xN{4{PjRzIN88US=>MXjTRW5ITVJ?
COLO-684MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{XCSWlEPTB;MUOuOFU1OSEQvF2=NYi4[|dZW0GQR1XS
RPMI-7951NVrESZFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfGdI5UUUN3ME2xN{42OTN4IN88US=>M{j1S3NCVkeHUh?=
A101DNULYTlExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nsS2lEPTB;MUOuOVM1QSEQvF2=MYLTRW5ITVJ?
KE-37NVzSN2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DIUGlEPTB;MUOuOVg5PyEQvF2=M{X5d3NCVkeHUh?=
SiHaNYf5SllST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPGT5VtUUN3ME2xN{45OzR4IN88US=>MXPTRW5ITVJ?
NCI-H226MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTF|Lki4NFgh|ryPM4O0OHNCVkeHUh?=
DBNF3HXGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTF|Lkm5Nlgh|ryPMXrTRW5ITVJ?
HT-1197M3jNXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVXJR|UxRTF2LkC4NFkh|ryPM{nVRXNCVkeHUh?=
SBC-5MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXITWM2OD1zND6xN|YzKM7:TR?=NFe1UFlUSU6JRWK=
VMRC-RCZNXHuR2pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\WPGlEPTB;MUSuOVc4PCEQvF2=M1:4ZXNCVkeHUh?=
697NGjuVVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfPd5p6UUN3ME2xOE43OjdizszNM3vV[3NCVkeHUh?=
OMC-1M2r6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTF2Lke4PFgh|ryPNF7N[XBUSU6JRWK=
SKG-IIIaM1jpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjJWlVUUUN3ME2xOE45ODBzIN88US=>NIjRO5lUSU6JRWK=
DOKMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXj1VXBGUUN3ME2xOE46QTN|IN88US=>MVLTRW5ITVJ?
NCI-H2029NFvDPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHTWXBKSzVyPUG1MlM3ODJizszNNIDFPGxUSU6JRWK=
NCI-H2009NX7SNWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfqNFM3UUN3ME2xOU42ODl3IN88US=>NWn2V3E4W0GQR1XS
LK-2NFHRbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rEWGlEPTB;MUWuOlQ1QSEQvF2=NFP0Z25USU6JRWK=
NCI-H661NEKxWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\Yd3JwUUN3ME2xOU46ODd3IN88US=>MnXCV2FPT0WU
GT3TKBNWTHVVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYXaOoZNUUN3ME2xOk4xPjd4IN88US=>Mk\oV2FPT0WU
GP5dNEXSNppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYjSfHZbUUN3ME2xOk4{PDJizszNNGnFVplUSU6JRWK=
SK-MEL-2MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEnH[mZKSzVyPUG2MlQ1QDVizszNNXHweHNVW0GQR1XS
SK-UT-1NX;ZTWhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnjRTWM2OD1zNj61OlUh|ryPM4L0SHNCVkeHUh?=
NB7MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWnOWGlJUUN3ME2xOk43QTdzIN88US=>NIS1VGJUSU6JRWK=
NCI-H460Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2X3dmlEPTB;MU[uO|MzPiEQvF2=MmPJV2FPT0WU
8305CNGnBdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUHJR|UxRTF4Lke4O|ch|ryPNH7QWGdUSU6JRWK=
CaR-1NHTqU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTF4LkixNVEh|ryPMlL4V2FPT0WU
D-247MGM3rtRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{HwZ2lEPTB;MU[uPFYzPSEQvF2=MXXTRW5ITVJ?
LoVoNXrTNoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fQSmlEPTB;MU[uPVQ5QCEQvF2=MWjTRW5ITVJ?
NCI-H2405MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rDSGlEPTB;MUeuNVkxQCEQvF2=MmnDV2FPT0WU
AU565NF7KbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnXeYVHUUN3ME2xO{4zOjVizszNNHnieXhUSU6JRWK=
OCI-AML2M4jzemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3HOTGlEPTB;MUeuOVMyPyEQvF2=NUOxOFVLW0GQR1XS
22RV1NYXTdlJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTF5LkW4PFQh|ryPMVnTRW5ITVJ?
HT-144M{PTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF7ydHVKSzVyPUG3MlY2QThizszNNYLHToJTW0GQR1XS
HuO9MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoPWTWM2OD1zNz63NFMyKM7:TR?=NYHFb3VIW0GQR1XS
DaoyMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUHJR|UxRTF5LkexPFQh|ryPNXHpfIhXW0GQR1XS
SJRH30NXfPfJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHJfVY4UUN3ME2xO{45PDh7IN88US=>MV\TRW5ITVJ?
CHL-1M{PkWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTF5LkmyOFkh|ryPMUjTRW5ITVJ?
J82MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M130dmlEPTB;MUeuPVY{PSEQvF2=MV;TRW5ITVJ?
COR-L23MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TJWmlEPTB;MUiuNFAyOSEQvF2=MnfHV2FPT0WU
SNU-C2BM1rDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7rfYV2UUN3ME2xPE4zOjd4IN88US=>MnXIV2FPT0WU
NCI-H1770NITNR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnywTWM2OD1zOD60OlE2KM7:TR?=M2XqXnNCVkeHUh?=
MHH-PREB-1M4LlXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF\LbYxKSzVyPUG4MlU3QTdizszNNHHKfmxUSU6JRWK=
ES3NEL6WIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjoU2RZUUN3ME2xPE42QDh|IN88US=>MXvTRW5ITVJ?
MDA-MB-231MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFLz[4JKSzVyPUG4MlY2ODJizszNMnnPV2FPT0WU
MN-60MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfD[4FKSzVyPUG5MlA2QTJizszNNGexbJlUSU6JRWK=
EPLC-272HM2L3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLwdmhbUUN3ME2xPU4{PzB6IN88US=>NEnzZpdUSU6JRWK=
SW948M2PibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XXUGlEPTB;MUmuN|k{PCEQvF2=MnjVV2FPT0WU
MOLT-13M3K5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTF7LkS1OFYh|ryPM3HOU3NCVkeHUh?=
HL-60NIH3eodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHeydXZKSzVyPUKwMlIyPDFizszNNFv4cVFUSU6JRWK=
CP50-MEL-BNXfFTJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1PlWWlEPTB;MkCuOFc1QCEQvF2=M4T0dXNCVkeHUh?=
NTERA-S-cl-D1NUPUc25oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LtcGlEPTB;MkCuOFk4QCEQvF2=M3S0SXNCVkeHUh?=
KINGS-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTJyLke5Olch|ryPNUjDe5U1W0GQR1XS
DOHH-2M37Edmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLCTWM2OD1{MD65NFYh|ryPNHH6Vm1USU6JRWK=
BB65-RCCNYTN[oprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{H1bGlEPTB;MkCuPVI5PSEQvF2=MmL6V2FPT0WU
NB12M4m1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjLTWM2OD1{MT6wN|k1KM7:TR?=NVvrPYJ4W0GQR1XS
KY821NFHhWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJzLkW4NkDPxE1?Mn;iV2FPT0WU
PSN1NXjobo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIrrUWVKSzVyPUKxMlY1PTNizszNNXriSGdWW0GQR1XS
EGI-1Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjNTWM2OD1{MT63OFU1KM7:TR?=NV;BdZUzW0GQR1XS
CTV-1M1jpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTJ{LkOwN|Eh|ryPMXzTRW5ITVJ?
TI-73NGC5RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFH2XlBKSzVyPUKyMlM1QThizszNM3XTZnNCVkeHUh?=
LCLC-103HMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnzJTWM2OD1{Mj60O|UzKM7:TR?=MnnkV2FPT0WU
D-542MGNXPodlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\aToZKSzVyPUKyMlU2PThizszNMWjTRW5ITVJ?
ATN-1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nuVmlEPTB;MkKuOlQ{QSEQvF2=NGHWfW9USU6JRWK=
SK-MEL-1NF3qPJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPNTWM2OD1{Mj64N|Y5KM7:TR?=Mn3kV2FPT0WU
HDLM-2MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjZRVFwUUN3ME2yN{4yPDd6IN88US=>NVL2OmFuW0GQR1XS
UM-UC-3MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTzTWM2OD1{Mz6xPVQ1KM7:TR?=M3zWfXNCVkeHUh?=
NCI-H1573MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjkVGJSUUN3ME2yN{41PjhzIN88US=>NFfVNnlUSU6JRWK=
NCI-H520Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\QfFJ6UUN3ME2yN{41QTR6IN88US=>MVTTRW5ITVJ?
ESS-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3K4S2lEPTB;MkOuPFA2QSEQvF2=MULTRW5ITVJ?
COR-L88MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIGzSlNKSzVyPUKzMlk1PzVizszNNVrrcIFxW0GQR1XS
TGBC24TKBMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;mZZlKSzVyPUK0MlA{OTJizszNMYfTRW5ITVJ?
HCC1937M1\ubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvuZottUUN3ME2yOE4yKM7:TR?=MkfwV2FPT0WU
RS4-11MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTJ2LkG0NkDPxE1?NHzwWnZUSU6JRWK=
HCC38MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYfJR|UxRTJ2LkKzPVQh|ryPMly3V2FPT0WU
RPMI-2650MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX7KS4FJUUN3ME2yOE43OTZ{IN88US=>M1TYdnNCVkeHUh?=
P12-ICHIKAWAMnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3CbWVKSzVyPUK0MlYzPThizszNMXrTRW5ITVJ?
YAPCMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTscYpKSzVyPUK0MlgzOTRizszNMkfNV2FPT0WU
NB13NG\YZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXMTWM2OD1{NT6yOlEyKM7:TR?=NXzURWpFW0GQR1XS
SK-N-ASMn\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYXJR|UxRTJ3Lki1PFQh|ryPNGrybHJUSU6JRWK=
SK-N-DZNYrBNphoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmq5TWM2OD1{Nj6wOFkh|ryPMWTTRW5ITVJ?
LS-411NNFLiZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTwTWM2OD1{Nj6yNFM5KM7:TR?=NYP6VXBTW0GQR1XS
NCI-H810NIrwd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2m1fWlEPTB;Mk[uN|EyOiEQvF2=NFj3WYFUSU6JRWK=
NCI-SNU-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LmcGlEPTB;Mk[uOVQ2PCEQvF2=NInxb25USU6JRWK=
HHM3vCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;sTWM2OD1{Nj61OVI6KM7:TR?=NFXVR5lUSU6JRWK=
U-2-OSMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfj[oZ3UUN3ME2yOk44Ozh{IN88US=>MXzTRW5ITVJ?
SF539MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HEc2lEPTB;Mk[uPFAyQCEQvF2=NWD6OXNQW0GQR1XS
NCI-H2052MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrTUGRKSzVyPUK3MlA5PiEQvF2=Mn33V2FPT0WU
A673MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTJ5LkKxNFIh|ryPM4jVZXNCVkeHUh?=
WM-115NHnjdYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\2OmlEPTB;MkeuO|c3PyEQvF2=M{D0[nNCVkeHUh?=
SW48M1L1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHFT3NkUUN3ME2yO{45ODB3IN88US=>MoX5V2FPT0WU
NOMO-1MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2X2VmlEPTB;MkeuPFU{OiEQvF2=NGnUe2xUSU6JRWK=
PC-3M4P0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofETWM2OD1{Nz64PVQyKM7:TR?=NWHzd3I4W0GQR1XS
UMC-11MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn[0TWM2OD1{Nz65N|Q{KM7:TR?=M4OyOHNCVkeHUh?=
U-118-MGNF22UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUDjdYVjUUN3ME2yPE4xOTJ|IN88US=>MUXTRW5ITVJ?
NCI-H2452MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkPjTWM2OD1{OD6wPFIzKM7:TR?=MmLIV2FPT0WU
CAMA-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVq3d2hTUUN3ME2yPE45PTZ2IN88US=>NUn1OIgxW0GQR1XS
MC-IXCMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX3JR|UxRTJ7LkKzOlYh|ryPMmHpV2FPT0WU
ES4NV7Mc5pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV3WdFNQUUN3ME2yPU4{OTd{IN88US=>NH7LUZlUSU6JRWK=
BHT-101NXXveJBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmf6TWM2OD1{OT6zNlEh|ryPM4L3XnNCVkeHUh?=
KP-4NFHjfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTJ7LkWxOkDPxE1?NYjIbHE6W0GQR1XS
CAL-54MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3WTWM2OD1{OT61OFQ2KM7:TR?=MWLTRW5ITVJ?
5637NXLqPZFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\sTWM2OD1{OT62OFIyKM7:TR?=M4\0SXNCVkeHUh?=
MOLT-16NHLITphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInoR29KSzVyPUK5MlczPjlizszNNUXGeJR2W0GQR1XS
Ca-SkiM{PR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTHZYE2UUN3ME2yPU46PDZizszNM1:zUHNCVkeHUh?=
AsPC-1Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\qVWlEPTB;M{CuNFIyOiEQvF2=MlfVV2FPT0WU
MSTO-211HMmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo[xTWM2OD1|MD6xOUDPxE1?M3X5XXNCVkeHUh?=
L-428MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYW0V294UUN3ME2zNE41ODVizszNNX3MRYg4W0GQR1XS
SW1463MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zxZmlEPTB;M{CuOVM5OyEQvF2=MVLTRW5ITVJ?
NCI-H1648M1nTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTNyLkW1O|Qh|ryPNXrQXGp1W0GQR1XS
CAKI-1NGjXVWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrNTXpKSzVyPUOwMlc4ODJizszNM3fmeHNCVkeHUh?=
YKG-1M17M[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XMUWlEPTB;M{GuNFI3OyEQvF2=M4nObXNCVkeHUh?=
A2058NGLxUnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnMcZZuUUN3ME2zNU4yOTZ2IN88US=>M1LNUXNCVkeHUh?=
A375MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjNN2VKSzVyPUOxMlE3QTZizszNMlXyV2FPT0WU
SNB75M4\vN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTNzLkK0N|Uh|ryPM2GwR3NCVkeHUh?=
SK-HEP-1NXKw[ldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrj[ZNKSzVyPUOxMlQzPzFizszNMWLTRW5ITVJ?
ME-180MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfiV3p3UUN3ME2zNU43PTR{IN88US=>NH61eXpUSU6JRWK=
NCI-H209MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3G0OmlEPTB;M{GuPFI1PyEQvF2=M37nWXNCVkeHUh?=
HC-1NHnWeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3fNN2lEPTB;M{KuNVQ1PiEQvF2=MoTwV2FPT0WU
LB373-MEL-DNXzSSYJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;EOHZKSzVyPUOyMlE6PzFizszNNWTnXYloW0GQR1XS
SNU-387NES1RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFz6N2pKSzVyPUOyMlMyQTFizszNNY\rbZBGW0GQR1XS
C32NFjmWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TEdGlEPTB;M{KuN|M2OyEQvF2=MWPTRW5ITVJ?
EW-13MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTN{Lkm0NFgh|ryPMYTTRW5ITVJ?
BFTC-905NVnXd5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnSxTWM2OD1|Mz61NVM3KM7:TR?=MoX6V2FPT0WU
NCI-H1299M3nqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnC[oF4UUN3ME2zN{42PjJzIN88US=>MV;TRW5ITVJ?
LU-135MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHS0NYVKSzVyPUOzMlgxOSEQvF2=NYjaNY1CW0GQR1XS
NCI-H2122NV;ENnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrtTWM2OD1|Mz65PVY3KM7:TR?=NUHuflFvW0GQR1XS
SK-LMS-1M4K2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTVXodrUUN3ME2zOE41OTB5IN88US=>NHnlN2hUSU6JRWK=
LNCaP-Clone-FGCNX22eIJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIq4fpFKSzVyPUO0Mlg2OTVizszNM{LyVHNCVkeHUh?=
NCI-H1092MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NULncVRwUUN3ME2zOU4zPzR5IN88US=>NIHnfIJUSU6JRWK=
MS-1NI\wU4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLOTWM2OD1|NT6zNFM5KM7:TR?=MlLRV2FPT0WU
KYSE-510MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHizeVdKSzVyPUO1MlUxPDJizszNMXLTRW5ITVJ?
NCI-H1793M1PL[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTN3Lk[1OFUh|ryPMo[xV2FPT0WU
MIA-PaCa-2NX7t[oNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPwTWM2OD1|Nj6wOFk3KM7:TR?=M2D4VHNCVkeHUh?=
EW-22M3K1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\semNKSzVyPUO2MlQxPzJizszNMnPIV2FPT0WU
IGR-1MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\SephKSzVyPUO2MlgyQDRizszNNYDwNY57W0GQR1XS
HT-1080M{DGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HDXGlEPTB;M{euNVI2KM7:TR?=NGTsRZVUSU6JRWK=
M14NG\hPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfLbYlbUUN3ME2zO{4yPjR{IN88US=>MWnTRW5ITVJ?
786-0MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHWfGdPUUN3ME2zO{4zPzl2IN88US=>MVTTRW5ITVJ?
MZ2-MELMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYewZ3BiUUN3ME2zO{41PTBzIN88US=>NWf4O5hVW0GQR1XS
NCI-H510ANWfhfotpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorrTWM2OD1|Nz65OFEzKM7:TR?=NVrlSIVOW0GQR1XS
LAN-6MkLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnjTWM2OD1|Nz65OVgzKM7:TR?=NH3WWo9USU6JRWK=
SW620M{\nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTN6LkS5O|Qh|ryPMYrTRW5ITVJ?
LB2241-RCCNF3Vc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1nKRmlEPTB;M{muPFIxPSEQvF2=Mn\6V2FPT0WU
Detroit562MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVjhZ4ZVUUN3ME20NE4yOjZ6IN88US=>M3\1OnNCVkeHUh?=
HNM1rDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTRyLkG3PFIh|ryPNEXjVI5USU6JRWK=
HCT-15M3HH[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzMUXJKSzVyPUSwMlU6ODdizszNNWn2V5J2W0GQR1XS
C2BBe1NFHDOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVzJR|UxRTRyLkmxOVch|ryPMVXTRW5ITVJ?
A498NF3WRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NE\3Z3hKSzVyPUSxMlMxOTVizszNMojiV2FPT0WU
SK-MEL-24NF;uV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jTfWlEPTB;NEGuOFczPSEQvF2=Ml25V2FPT0WU
OVCAR-5M{O2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTRzLke3Olch|ryPM2DyOHNCVkeHUh?=
NCI-H1792NWXlTJhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT2b21KUUN3ME20NU46QDJzIN88US=>M4SycHNCVkeHUh?=
KOSC-2Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzmTWM2OD12Mj6yOlk6KM7:TR?=MoTiV2FPT0WU
Mo-TNYXSc41iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M16ydmlEPTB;NEKuPFk2QCEQvF2=MUHTRW5ITVJ?
CFPAC-1NVn4bXBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{S4XGlEPTB;NEOuOFk1PCEQvF2=M2fLfnNCVkeHUh?=
CAL-51NEjxNHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mo\tTWM2OD12Mz61OlA2KM7:TR?=NUHxZ25sW0GQR1XS
RH-18NEfWToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTR|LkiwOUDPxE1?NIPDSndUSU6JRWK=
EC-GI-10NV;MUYZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFe5XnZKSzVyPUSzMlg{PDdizszNM2rZVHNCVkeHUh?=
HSC-2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HEZWlEPTB;NESuNFA6KM7:TR?=NU[5Sm5VW0GQR1XS
ML-2NX;vZ24xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HwRWlEPTB;NEWuNlYzOSEQvF2=NH7lZo1USU6JRWK=
KNS-81-FDMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUjJR|UxRTR3LkezOlUh|ryPNVLyb2RxW0GQR1XS
NB6MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTR4LkGxNUDPxE1?MnvQV2FPT0WU
MCF7MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvXUXVKSzVyPUS2MlU2OzNizszNNGjSXnRUSU6JRWK=
P30-OHKNUTISW11T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkHwTWM2OD12Nj64NVE4KM7:TR?=NWTJVlUxW0GQR1XS
BPH-1NGDpWoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf4bmpKSzVyPUS2Mlk5ODVizszNNGXsfHZUSU6JRWK=
U251MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mmf2TWM2OD12Nj65PVQh|ryPNEnsdFBUSU6JRWK=
MKN1MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTKUmVKSzVyPUS3MlUyOzdizszNMXjTRW5ITVJ?
A431Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HZTGlEPTB;NEeuPFM{QCEQvF2=MkPsV2FPT0WU
C8166Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkXjTWM2OD12OT6yNFM6KM7:TR?=NUPrV2JMW0GQR1XS
HELNVfZNW44T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrGTWM2OD12OT60NFY1KM7:TR?=NU\3RmROW0GQR1XS
RMG-IMlOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2XyXmlEPTB;NEmuOFQ1PCEQvF2=MVLTRW5ITVJ?
CAL-72NVy5U|lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFy2dINKSzVyPUS5MlYxPzVizszNM{LiXXNCVkeHUh?=
SW962MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnTSTWM2OD12OT65N|MzKM7:TR?=NWroPWNFW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).

Protocol(Only for Reference)

Kinase Assay:

[1]

Cellular receptor kinase phosphorylation assay Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.

Cell Assay:

[2]

Cell lines HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
Concentrations 1 nM - 10 μM
Incubation Time 72 hours
Method

Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.

Animal Study:

[3]

Animal Models BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
Formulation 0.5% carboxymethylcellulose (CMC)
Dosages 10, 30 or 100 mg/kg
Administration Oral daily

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Hu-Lowe DD, et al. Clin Cancer Res, 2008, 14(22), 7272-7283.

[2] Rossler, J. et al., Int J Cancer, 2011, 128(11), 2748-2758.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer December 2016 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02762513 Not yet recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center May 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3
NCT02636725 Recruiting Alveolar Soft Part Sarcoma|Soft Tissue Sarcomas Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University  ...more Breelyn Wilky|Merck Sharp & Dohme Corp.|Pfizer|University of Miami March 2016 Phase 2

view more

Chemical Information

Download Axitinib SDF
Molecular Weight (MW) 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AG 013736
Solubility (25°C) * In vitro DMSO 35 mg/mL warming (90.56 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name N-methyl-2-[[3-[(1E)-2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]-benzamide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

  • Pazopanib HCl (GW786034 HCl)

    Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

    Features:A multi-kinase inhibitor.

Recently Viewed Items

Tags: buy Axitinib | Axitinib ic50 | Axitinib price | Axitinib cost | Axitinib solubility dmso | Axitinib purchase | Axitinib manufacturer | Axitinib research buy | Axitinib order | Axitinib mouse | Axitinib chemical structure | Axitinib mw | Axitinib molecular weight | Axitinib datasheet | Axitinib supplier | Axitinib in vitro | Axitinib cell line | Axitinib concentration | Axitinib nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us